Fig. 6From: Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot studyGrand average of lead Cz of the P50 suppression paradigm, for the a) conditioning (“S1”) and b) testing stimuli (“S2”) showing no difference between group and time pointsBack to article page
